PMID- 37711815
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230917
IS  - 2223-4292 (Print)
IS  - 2223-4306 (Electronic)
IS  - 2223-4306 (Linking)
VI  - 13
IP  - 9
DP  - 2023 Sep 1
TI  - Drug-eluting beads bronchial arterial chemoembolization/bronchial arterial 
      infusion chemotherapy with and without PD-1 blockade for advanced non-small cell 
      lung cancer: a comparative single-center cohort study.
PG  - 6241-6256
LID - 10.21037/qims-23-287 [doi]
AB  - BACKGROUND: Drug-eluting beads bronchial arterial chemoembolization 
      (DEB-BACE)/bronchial artery infusion chemotherapy (BAI) have been investigated as 
      treatment options for advanced non-small cell lung cancer (NSCLC), especially for 
      those patients who develop refractoriness to or are intolerant to systemic 
      chemotherapy. This retrospective study aimed to compare the outcomes of 
      DEB-BACE/BAI with and without programmed cell death protein 1 (PD-1) blockade for 
      advanced NSCLC, and to investigate the effectiveness and safety of combination 
      regimens. METHODS: This retrospective cohort study included advanced NSCLC 
      patients who were intolerant to or were resistant to systemic chemotherapy, 
      radiotherapy, or molecular targeted therapy and underwent DEB-BACE/BAI between 
      October 2016 and October 2021 in Beijing Hospital, National Center of 
      Gerontology. A total of 84 advanced NSCLC patients (DEB-BACE/BAI + PD-1 blockade 
      group: group A, n=27; DEB-BACE/BAI: group B, n=57) were enrolled finally. The 
      embolic agent CalliSpheres (100-300, 300-500, or 500-700 microm) loaded with 
      gemcitabine (800 mg) was administered during the DEB-BACE procedure. The adverse 
      events (AEs) and outcomes were compared. Of these, the median progression-free 
      survival (PFS) and overall survival (OS) were compared via Kaplan-Meier (KM) 
      methods. Univariate and multivariate Cox regression analyses were used to 
      investigate the predictors of PFS and OS. RESULTS: KM methods showed that group A 
      had longer median PFS (12.0 vs. 3.0 months, P<0.001) and OS (27.0 vs. 8.0 months, 
      P<0.001) than group B. The predictors of PFS for DEB-BACE/BAI included tumor 
      diameter (P=0.013), immunotherapy (P<0.001), and DEB-BACE/BAI cycles (P=0.012), 
      whereas the predictors of OS included tumor diameter (P=0.021), extrapulmonary 
      metastases (P=0.041), immunotherapy (P<0.001), and DEB-BACE/BAI cycles (P=0.020). 
      The incidence rates of overall AEs in groups A and B were 40.7% (11/27) and 36.8% 
      (21/57), respectively, and no significant difference was found (P=0.731). Group A 
      had an incidence rate of 11.1% for grade 3 immunotherapy-related AEs (irAEs). 
      There were no incidences of ectopic embolization or spinal artery injury. 
      CONCLUSIONS: Compared with DEB-BACE/BAI, PD-1 blockade plus DEB-BACE/BAI could 
      improve the prognosis for advanced NSCLC despite the associated risk of grade 3 
      irAEs. The combination regimens are promising and safe approaches for advanced 
      NSCLC.
CI  - 2023 Quantitative Imaging in Medicine and Surgery. All rights reserved.
FAU - Xu, Sheng
AU  - Xu S
AD  - Department of Minimally Invasive Tumor Therapies Center, Beijing Hospital, 
      National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy 
      of Medical Sciences, Beijing, China.
FAU - Li, Yuan-Ming
AU  - Li YM
AD  - Department of Minimally Invasive Tumor Therapies Center, Beijing Hospital, 
      National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy 
      of Medical Sciences, Beijing, China.
FAU - Bie, Zhi-Xin
AU  - Bie ZX
AD  - Department of Minimally Invasive Tumor Therapies Center, Beijing Hospital, 
      National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy 
      of Medical Sciences, Beijing, China.
FAU - Li, Xiao-Guang
AU  - Li XG
AD  - Department of Minimally Invasive Tumor Therapies Center, Beijing Hospital, 
      National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy 
      of Medical Sciences, Beijing, China.
AD  - Graduate School of Peking Union Medical College, Chinese Academy of Medical 
      Sciences, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20230810
PL  - China
TA  - Quant Imaging Med Surg
JT  - Quantitative imaging in medicine and surgery
JID - 101577942
PMC - PMC10498207
OTO - NOTNLM
OT  - Non-small cell lung cancer (NSCLC)
OT  - chemoembolization
OT  - drug-eluting beads
OT  - immunotherapy
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://qims.amegroups.com/article/view/10.21037/qims-23-287/coif). The authors 
      have no conflicts of interest to declare.
EDAT- 2023/09/15 06:43
MHDA- 2023/09/15 06:44
PMCR- 2023/09/01
CRDT- 2023/09/15 03:58
PHST- 2023/03/08 00:00 [received]
PHST- 2023/07/28 00:00 [accepted]
PHST- 2023/09/15 06:44 [medline]
PHST- 2023/09/15 06:43 [pubmed]
PHST- 2023/09/15 03:58 [entrez]
PHST- 2023/09/01 00:00 [pmc-release]
AID - qims-13-09-6241 [pii]
AID - 10.21037/qims-23-287 [doi]
PST - ppublish
SO  - Quant Imaging Med Surg. 2023 Sep 1;13(9):6241-6256. doi: 10.21037/qims-23-287. 
      Epub 2023 Aug 10.